Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.3% – Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price traded down 6.3% during mid-day trading on Thursday . The company traded as low as $30.29 and last traded at $30.6360. Approximately 7,248,392 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 29,921,127 shares. The stock had previously closed at $32.70.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Canaccord Genuity Group set a $32.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 5th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research note on Friday, May 22nd. Finally, Leerink Partners boosted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $29.37.

Hims & Hers Health Trading Down 6.6%

The business has a fifty day moving average price of $27.52 and a 200 day moving average price of $26.46. The firm has a market capitalization of $7.07 billion, a price-to-earnings ratio of -338.80, a P/E/G ratio of 47.12 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.20 EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the sale, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 163,973 shares of company stock valued at $4,859,194 over the last quarter. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Sigma Planning Corp grew its position in shares of Hims & Hers Health by 1.5% during the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after acquiring an additional 388 shares during the last quarter. BAM Wealth Management LLC boosted its position in shares of Hims & Hers Health by 5.6% during the 4th quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock valued at $240,000 after purchasing an additional 393 shares in the last quarter. Xponance Inc. grew its position in Hims & Hers Health by 1.5% in the third quarter. Xponance Inc. now owns 28,195 shares of the company’s stock worth $1,599,000 after buying an additional 419 shares during the last quarter. Captrust Financial Advisors raised its position in shares of Hims & Hers Health by 3.1% during the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock worth $728,000 after purchasing an additional 443 shares during the period. Finally, Sherman Porfolios LLC raised its holdings in Hims & Hers Health by 10.5% during the 3rd quarter. Sherman Porfolios LLC now owns 4,934 shares of the company’s stock worth $280,000 after buying an additional 467 shares during the period. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.